Lifestance Health stock hits 52-week high at $13.57

Lifestance Health Group Inc's stock surged to a 52-week high of $13.57, marking a substantial 168.07% increase in value over the past year. The company's market capitalization reached an impressive $5.16 billion, reflecting strong investor confidence and growth potential within the mental health services industry. LifeStance Health reported a remarkable 20% revenue growth over the last twelve months, and analysts anticipate a positive year with net income growth.

According to InvestingPro, the stock is trading slightly above its Fair Value and has been placed on the Most Overvalued watchlist. The platform provides 13 exclusive tips for LFST subscribers. In a separate report, LifeStance Health exceeded Wall Street expectations in Q2 2026, reporting adjusted earnings of $0.06 per share, double the expected $0.03 per share, and revenue of $435.35 million, surpassing the anticipated $414.38 million.

The company's full-year outlook was also revised upwards following a 26% rise in revenue, a 94% increase in adjusted EBITDA, and a boost in net income. Growth was fueled by increased visit volumes and higher revenue per visit, with visits totaling 2.6 million, a 19% increase from the previous year. Two investment firms, KeyBanc and Canaccord, have raised their price targets to $15.00, maintaining Overweight and Buy ratings, respectively, highlighting LifeStance Health's leadership in outpatient mental health and specialty care in treatment-resistant depression therapies.